Thursday, 16 January 2014

Ranbaxy likely to tie-up with MNC to source Diovan APIs .

Diovan was the drug which was off-patented in September 2012 and Ranbaxy has a first-to-file (FTF) status over it. This means they will get six months of marketing exclusivity in the market. 

Read more at:

No comments:

Post a Comment